<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567826</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 09-1294</org_study_id>
    <secondary_id>IF1292822</secondary_id>
    <nct_id>NCT01567826</nct_id>
  </id_info>
  <brief_title>Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy</brief_title>
  <acronym>YELLOW</acronym>
  <official_title>Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy. (YELLOW Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annapoorna Kini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the regression of yellow plaque content of the lipid pool after
      aggressive lipid therapy by utilizing NIR spectroscopy. Statin therapy using Rosuvastatin
      10-40 mg will be compared to the statin therapy of either Atorvastatin or Simvastatin. This
      is a single site study. A total of 100 subjects will randomized, of which 40 will receive
      intensive lipid therapy (Rosuvastatin 40mg) and 40 will receive standard care lipid lowering
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery disease (CHD) remains to be a leading cause of death in most countries (1)
      (2). It is well known that reducing cholesterol level by statin therapy is associated with
      significant reduction in plaque burden. REVERSAL (3) and ASTEROID (4) trials showed that in
      patients with coronary artery disease lipid-lowering with atorvastatin or rosuvastatin
      respectively reduced progression of coronary atherosclerosis and even cause repression of
      some lesions. CHD clinical events are related to plaque instability due to lipid content
      within the atherosclerotic plaque. High dose atorvastatin has shown to reduce the plaque
      lipid contents on serial IVUS analysis at 12 months. Therefore reduction in lipid content and
      thereby the plaque burden by lipid lowering therapy may stabilize the plaque and reduce
      cardiovascular events. High sensitivity C-reactive Protein (HsCRP) is an inflammatory
      biomarker that independently predicts future vascular events. In JUPITER (5) trial
      rosuvastatin (Crestor) significantly reduced the incidence of major cardiovascular events in
      apparently healthy people with elevated HsCRP. IVUS was utilized to demonstrate change in
      coronary artery vessel wall morphology over a relatively short period of time, but provided
      no data on the lipid content in the vessel wall. The application of NIR spectroscopy to
      identify lipid deposition within coronary arteries has been validated in ex vivo studies.
      Infrared spectra are collected as follows: Light of discrete wavelengths from a laser is
      directed onto the tissue sample via glass fibers. Light scattered from the samples is
      collected in fibers and launched into a spectrometer. The plot of signal intensity as a
      function of wavelength was used to develop chemometric models to discriminate lipid-cores
      from non-atherosclerotic tissue, and from atherosclerotic tissue that is predominantly
      fibrotic and from blood elements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipiscan - Lipid Core Burden Index (LCBI)</measure>
    <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
    <description>The regression of yellow plaque content from the atherosclerotic lipid pool after statin therapy by utilizing NIR spectroscopy as compared from baseline to 6-8 weeks after intervention. Spectroscopic information obtained from raw spectra was transformed into a probability of lipid core that was mapped to a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow. Analyses were performed offline using the Matlab-based software, as previously published. Yellow pixels within the analyzed segment were divided by all viable pixels to generate the lipid-core burden index (LCBI). The maximal value of LCBI for each nonculprit obstructive lesion was recorded and used for comparison.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LCBI4mm Max</measure>
    <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
    <description>LCBI4mm max = change in lipid-core burden index at the 4-mm maximal segment. Spectroscopic information obtained from raw spectra was transformed into a probability of lipid core that was mapped to a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow. Yellow pixels within the analyzed segment were divided by all viable pixels to generate the lipid-core burden index (LCBI). The maximal value of LCBI for each nonculprit obstructive lesion was recorded and used for comparison.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LCBI4mm Max</measure>
    <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
    <description>Change in LCBI4mm max at 6-8 weeks after intervention as compared to baseline. LCBI4mm max = change in lipid-core burden index at the 4-mm maximal segment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LCBI, Lesion</measure>
    <time_frame>at baseline and at 6-8 weeks post intervention</time_frame>
    <description>Change in LCBI at 6-8 weeks after intervention as compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intravascular Ultrasound (IVUS) Parameters</measure>
    <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
    <description>Change in atheroma volume and lumen CSA on IVUS as related to change in yellow plaque index as compared from baseline to 6-8 weeks after intervention.
Data not analyzed. Data not available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Flow Reserve (FFR) Value</measure>
    <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
    <description>Change in FFR as related to change in yellow plaque index as compared from baseline to 6-8 weeks after intervention. Fractional flow reserve (FFR), defined as the ratio of maximum flow in the presence of a stenosis to normal maximum flow, is a lesion-specific index of stenosis severity that can be calculated by simultaneous measurement of mean arterial, distal coronary, and central venous pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter Stenosis</measure>
    <time_frame>Baseline and 6-8 weeks post intervention</time_frame>
    <description>Percentage stenosis of vessel diameter in the analysis segment of nontarget lesions as measured by angiography that remained &gt;70%, after successful PCI of the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post PCI Cardiac Enzymes</measure>
    <time_frame>at 6-8 weeks after intervention</time_frame>
    <description>Correlation of yellow plaque index with post procedure CK-MB, Troponin-I release.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>at 6-8 weeks after intervention</time_frame>
    <description>MACE defined as a combined clinical endpoint of death, MI (Q wave or non Q-wave with CK-MB &gt;3 times above the upper normal limit (48 U/L), urgent revascularization or stroke at 30 days and 1 year. Details reported in adverse events section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry - HsCRP</measure>
    <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
    <description>Correlation of yellow plaque index with changes in levels of blood HsCRP as compared from baseline to 6-8 weeks after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>standard of care lipid therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard-care lipid-lowering therapy: Zocor or Lipitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aggressive lipid therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aggressive lipid therapy: Crestor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care lipid therapy</intervention_name>
    <description>Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Zocor, Lipitor [any dose] and Crestor [less than 40mg]</description>
    <arm_group_label>standard of care lipid therapy</arm_group_label>
    <other_name>Zocor</other_name>
    <other_name>Lipitor</other_name>
    <other_name>(Zocor, Lipitor, Crestor)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aggressive lipid therapy</intervention_name>
    <description>Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.</description>
    <arm_group_label>aggressive lipid therapy</arm_group_label>
    <other_name>Rosuvastatin</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient &gt; 18 years of age and willing to participate

          -  Stable patients who will undergo cardiac catheterization and PCI (intent to stent)

          -  Patient is willing to go on a cholesterol lowering medication for the duration of the
             study and willing to change statin therapy to the randomized statin therapy regardless
             of previous statin therapy and dose (e.g. Atorvastatin 80 mg) Patients that are
             screened for this study and are receiving another Statin such as Pravachol will be
             required to be willing to change their therapy to Rosuvastatin as per is
             randomization. If patients are receiving another statin, such as pravachol, or any
             other agent, and are at appropriate Lipid levels, they will be permitted to continue
             this therapy (if randomized to the standard therapy arm). There are a virtually
             unlimited number of possible scenarios for potential combination of all Lipid lowering
             agents at the time of enrollment that patients may be taking.

          -  Signed written Informed Consent

          -  Women of childbearing potential must agree to be on an acceptable method of birth
             control/contraceptive such as barrier method (condoms/diaphragm); hormonal
             contraceptives (birth control pills, implants (Norplant) or injections
             (Depo-Provera)); Intrauterine Device; or abstinence (no sexual activity).

          -  Fluency in English and/or Spanish

        Exclusion Criteria:

          -  Patients who have acute myocardial infarction (Q wave or non-Q wave with CK-MB &gt; 5
             times above the upper normal (31.5 ng/ml) within 72 hours)

          -  Patients who are in cardiogenic shock

          -  Patients with left main disease or restenotic lesions

          -  Patients with elevated CK-MB (&gt; 6.5 ng/ml) or Tnl (&gt; 0.5ng/L) at baseline

          -  Patients with platelet count &lt; 100,000 cell/mm3

          -  Patients who have co-morbidity which reduces life expectancy to one year

          -  Patients who are currently participating in another investigational drug/device study

          -  Patients with known hypersensitivity to HMG CO-A reductase therapy (statins)

          -  Patients with liver disease

          -  Patient with creatinine &gt; 2.0 mg/dL

          -  Pregnant women and women of childbearing potential who intend to have children during
             the duration of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annapoorna Kini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kini AS, Baber U, Kovacic JC, Limaye A, Ali ZA, Sweeny J, Maehara A, Mehran R, Dangas G, Mintz GS, Fuster V, Narula J, Sharma SK, Moreno PR. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013 Jul 2;62(1):21-9. doi: 10.1016/j.jacc.2013.03.058. Epub 2013 May 1.</citation>
    <PMID>23644090</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2012</study_first_posted>
  <results_first_submitted>May 10, 2016</results_first_submitted>
  <results_first_submitted_qc>January 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2017</results_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Annapoorna Kini</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>YELLO</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>lipid therapy</keyword>
  <keyword>Statin therapy</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>CHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>779 patients consecutive patients with chronic stable angina presenting for elective coronary angiography were screened from May 21, 2010 until Jan 10, 2012. 87 participants met criteria and were randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care Lipid Therapy</title>
          <description>standard-care lipid-lowering therapy: Zocor or Lipitor
standard of care lipid therapy: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Zocor, Lipitor [any dose] and Crestor [less than 40mg]</description>
        </group>
        <group group_id="P2">
          <title>Aggressive Lipid Therapy</title>
          <description>aggressive lipid therapy: Crestor
Aggressive lipid therapy: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care Lipid Therapy</title>
          <description>standard-care lipid-lowering therapy: Zocor or Lipitor
standard of care lipid therapy: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Zocor, Lipitor [any dose] and Crestor [less than 40mg]</description>
        </group>
        <group group_id="B2">
          <title>Aggressive Lipid Therapy</title>
          <description>aggressive lipid therapy: Crestor
Aggressive lipid therapy: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" spread="9.8"/>
                    <measurement group_id="B2" value="64.4" spread="9.29"/>
                    <measurement group_id="B3" value="63.6" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current tobacco use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypercholesterolemia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes mellitus</title>
          <description>(treated with insulin)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior CVA/TIA</title>
          <description>Cerebrovascular accident (CVA); Transient ischemic attack (TIA)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous MI</title>
          <description>Myocardial infarction (MI)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous PCI</title>
          <description>Percutaneous coronary intervention (PCI)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Statin Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta-blocker use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ACE-I/ARB use</title>
          <description>Angiotensin-converting enzyme inhibitor (ACE-I); Angiotensin receptor blocker (ARB)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="1.3"/>
                    <measurement group_id="B2" value="1.0" spread="0.3"/>
                    <measurement group_id="B3" value="1.04" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LAD Coronary vessel</title>
          <description>Left anterior descending (LAD)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LCx coronary vessel</title>
          <description>Left circumflex (LCx)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RCA coronary vessel</title>
          <description>Right coronary artery (RCA)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lipiscan - Lipid Core Burden Index (LCBI)</title>
        <description>The regression of yellow plaque content from the atherosclerotic lipid pool after statin therapy by utilizing NIR spectroscopy as compared from baseline to 6-8 weeks after intervention. Spectroscopic information obtained from raw spectra was transformed into a probability of lipid core that was mapped to a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow. Analyses were performed offline using the Matlab-based software, as previously published. Yellow pixels within the analyzed segment were divided by all viable pixels to generate the lipid-core burden index (LCBI). The maximal value of LCBI for each nonculprit obstructive lesion was recorded and used for comparison.</description>
        <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
        <population>Data were not available in 17 patients because of loss to follow-up (n = 5), incorrect image formatting that could not be recovered at the time of core laboratory analysis (n = 5), NIRS console/catheter malfunction at the time of index PCI (n = 3), and loss of disc integrity or corruption before core laboratory analysis (n = 4).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Lipid Therapy</title>
            <description>standard-care lipid-lowering therapy: Zocor or Lipitor
standard of care lipid therapy: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Zocor, Lipitor [any dose] and Crestor [less than 40mg]</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Lipid Therapy</title>
            <description>aggressive lipid therapy: Crestor
Aggressive lipid therapy: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Lipiscan - Lipid Core Burden Index (LCBI)</title>
          <description>The regression of yellow plaque content from the atherosclerotic lipid pool after statin therapy by utilizing NIR spectroscopy as compared from baseline to 6-8 weeks after intervention. Spectroscopic information obtained from raw spectra was transformed into a probability of lipid core that was mapped to a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow. Analyses were performed offline using the Matlab-based software, as previously published. Yellow pixels within the analyzed segment were divided by all viable pixels to generate the lipid-core burden index (LCBI). The maximal value of LCBI for each nonculprit obstructive lesion was recorded and used for comparison.</description>
          <population>Data were not available in 17 patients because of loss to follow-up (n = 5), incorrect image formatting that could not be recovered at the time of core laboratory analysis (n = 5), NIRS console/catheter malfunction at the time of index PCI (n = 3), and loss of disc integrity or corruption before core laboratory analysis (n = 4).</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline LCBI, lesion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="29.6" upper_limit="174.6"/>
                    <measurement group_id="O2" value="132.4" lower_limit="99.0" upper_limit="201.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up LCBI, lesion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" lower_limit="38.2" upper_limit="204.3"/>
                    <measurement group_id="O2" value="99.8" lower_limit="64.2" upper_limit="159.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LCBI4mm Max</title>
        <description>LCBI4mm max = change in lipid-core burden index at the 4-mm maximal segment. Spectroscopic information obtained from raw spectra was transformed into a probability of lipid core that was mapped to a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow. Yellow pixels within the analyzed segment were divided by all viable pixels to generate the lipid-core burden index (LCBI). The maximal value of LCBI for each nonculprit obstructive lesion was recorded and used for comparison.</description>
        <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
        <population>Data were not available in 17 patients because of loss to follow-up (n = 5), incorrect image formatting that could not be recovered at the time of core laboratory analysis (n = 5), NIRS console/catheter malfunction at the time of index PCI (n = 3), and loss of disc integrity or corruption before core laboratory analysis (n = 4).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Lipid Therapy</title>
            <description>standard-care lipid-lowering therapy: Zocor or Lipitor
standard of care lipid therapy: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Zocor, Lipitor [any dose] and Crestor [less than 40mg]</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Lipid Therapy</title>
            <description>aggressive lipid therapy: Crestor
Aggressive lipid therapy: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>LCBI4mm Max</title>
          <description>LCBI4mm max = change in lipid-core burden index at the 4-mm maximal segment. Spectroscopic information obtained from raw spectra was transformed into a probability of lipid core that was mapped to a red-to-yellow color scale, with the low probability of lipid shown as red and the high probability of lipid shown as yellow. Yellow pixels within the analyzed segment were divided by all viable pixels to generate the lipid-core burden index (LCBI). The maximal value of LCBI for each nonculprit obstructive lesion was recorded and used for comparison.</description>
          <population>Data were not available in 17 patients because of loss to follow-up (n = 5), incorrect image formatting that could not be recovered at the time of core laboratory analysis (n = 5), NIRS console/catheter malfunction at the time of index PCI (n = 3), and loss of disc integrity or corruption before core laboratory analysis (n = 4).</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline LCBI4mm max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356.7" lower_limit="145.2" upper_limit="509.2"/>
                    <measurement group_id="O2" value="490.6" lower_limit="363.8" upper_limit="689.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up LCBI4mm max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385.7" lower_limit="139.2" upper_limit="510.9"/>
                    <measurement group_id="O2" value="336.1" lower_limit="252.3" upper_limit="479.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in LCBI4mm Max</title>
        <description>Change in LCBI4mm max at 6-8 weeks after intervention as compared to baseline. LCBI4mm max = change in lipid-core burden index at the 4-mm maximal segment.</description>
        <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
        <population>Data were not available in 17 patients because of loss to follow-up (n = 5), incorrect image formatting that could not be recovered at the time of core laboratory analysis (n = 5), NIRS console/catheter malfunction at the time of index PCI (n = 3), and loss of disc integrity or corruption before core laboratory analysis (n = 4).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Lipid Therapy</title>
            <description>standard-care lipid-lowering therapy: Zocor or Lipitor</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Lipid Therapy</title>
            <description>aggressive lipid therapy: Crestor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LCBI4mm Max</title>
          <description>Change in LCBI4mm max at 6-8 weeks after intervention as compared to baseline. LCBI4mm max = change in lipid-core burden index at the 4-mm maximal segment.</description>
          <population>Data were not available in 17 patients because of loss to follow-up (n = 5), incorrect image formatting that could not be recovered at the time of core laboratory analysis (n = 5), NIRS console/catheter malfunction at the time of index PCI (n = 3), and loss of disc integrity or corruption before core laboratory analysis (n = 4).</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="-36.1" upper_limit="44.7"/>
                    <measurement group_id="O2" value="-149.1" lower_limit="-210.9" upper_limit="-42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in LCBI, Lesion</title>
        <description>Change in LCBI at 6-8 weeks after intervention as compared to baseline</description>
        <time_frame>at baseline and at 6-8 weeks post intervention</time_frame>
        <population>Data were not available in 17 patients because of loss to follow-up (n = 5), incorrect image formatting that could not be recovered at the time of core laboratory analysis (n = 5), NIRS console/catheter malfunction at the time of index PCI (n = 3), and loss of disc integrity or corruption before core laboratory analysis (n = 4).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Lipid Therapy</title>
            <description>standard-care lipid-lowering therapy: Zocor or Lipitor</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Lipid Therapy</title>
            <description>aggressive lipid therapy: Crestor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LCBI, Lesion</title>
          <description>Change in LCBI at 6-8 weeks after intervention as compared to baseline</description>
          <population>Data were not available in 17 patients because of loss to follow-up (n = 5), incorrect image formatting that could not be recovered at the time of core laboratory analysis (n = 5), NIRS console/catheter malfunction at the time of index PCI (n = 3), and loss of disc integrity or corruption before core laboratory analysis (n = 4).</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="-7.7" upper_limit="22.1"/>
                    <measurement group_id="O2" value="-22.5" lower_limit="-59.2" upper_limit="-3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intravascular Ultrasound (IVUS) Parameters</title>
        <description>Change in atheroma volume and lumen CSA on IVUS as related to change in yellow plaque index as compared from baseline to 6-8 weeks after intervention.
Data not analyzed. Data not available.</description>
        <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Lipid Therapy</title>
            <description>standard-care lipid-lowering therapy: Zocor or Lipitor
standard of care lipid therapy: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Zocor, Lipitor [any dose] and Crestor [less than 40mg]</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Lipid Therapy</title>
            <description>aggressive lipid therapy: Crestor
Aggressive lipid therapy: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Intravascular Ultrasound (IVUS) Parameters</title>
          <description>Change in atheroma volume and lumen CSA on IVUS as related to change in yellow plaque index as compared from baseline to 6-8 weeks after intervention.
Data not analyzed. Data not available.</description>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Total atheroma volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.7" spread="61.7"/>
                    <measurement group_id="O2" value="195.8" spread="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-8 weeks Total atheroma volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.6" spread="63.9"/>
                    <measurement group_id="O2" value="209.6" spread="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Lumen CSA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.6"/>
                    <measurement group_id="O2" value="2.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-8 weeks Lumen CSA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.7"/>
                    <measurement group_id="O2" value="2.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fractional Flow Reserve (FFR) Value</title>
        <description>Change in FFR as related to change in yellow plaque index as compared from baseline to 6-8 weeks after intervention. Fractional flow reserve (FFR), defined as the ratio of maximum flow in the presence of a stenosis to normal maximum flow, is a lesion-specific index of stenosis severity that can be calculated by simultaneous measurement of mean arterial, distal coronary, and central venous pressure.</description>
        <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Lipid Therapy</title>
            <description>standard-care lipid-lowering therapy: Zocor or Lipitor</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Lipid Therapy</title>
            <description>aggressive lipid therapy: Crestor</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Flow Reserve (FFR) Value</title>
          <description>Change in FFR as related to change in yellow plaque index as compared from baseline to 6-8 weeks after intervention. Fractional flow reserve (FFR), defined as the ratio of maximum flow in the presence of a stenosis to normal maximum flow, is a lesion-specific index of stenosis severity that can be calculated by simultaneous measurement of mean arterial, distal coronary, and central venous pressure.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.1"/>
                    <measurement group_id="O2" value="0.73" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.1"/>
                    <measurement group_id="O2" value="0.75" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diameter Stenosis</title>
        <description>Percentage stenosis of vessel diameter in the analysis segment of nontarget lesions as measured by angiography that remained &gt;70%, after successful PCI of the target lesion.</description>
        <time_frame>Baseline and 6-8 weeks post intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Lipid Therapy</title>
            <description>standard-care lipid-lowering therapy: Zocor or Lipitor</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Lipid Therapy</title>
            <description>aggressive lipid therapy: Crestor</description>
          </group>
        </group_list>
        <measure>
          <title>Diameter Stenosis</title>
          <description>Percentage stenosis of vessel diameter in the analysis segment of nontarget lesions as measured by angiography that remained &gt;70%, after successful PCI of the target lesion.</description>
          <units>percentage of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9"/>
                    <measurement group_id="O2" value="79.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post PCI Cardiac Enzymes</title>
        <description>Correlation of yellow plaque index with post procedure CK-MB, Troponin-I release.</description>
        <time_frame>at 6-8 weeks after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Lipid Therapy</title>
            <description>standard-care lipid-lowering therapy: Zocor or Lipitor</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Lipid Therapy</title>
            <description>aggressive lipid therapy: Crestor</description>
          </group>
        </group_list>
        <measure>
          <title>Post PCI Cardiac Enzymes</title>
          <description>Correlation of yellow plaque index with post procedure CK-MB, Troponin-I release.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CK-MB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="9.0"/>
                    <measurement group_id="O2" value="3.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.0"/>
                    <measurement group_id="O2" value="0.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Events (MACE)</title>
        <description>MACE defined as a combined clinical endpoint of death, MI (Q wave or non Q-wave with CK-MB &gt;3 times above the upper normal limit (48 U/L), urgent revascularization or stroke at 30 days and 1 year. Details reported in adverse events section.</description>
        <time_frame>at 6-8 weeks after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Lipid Therapy</title>
            <description>standard-care lipid-lowering therapy: Zocor or Lipitor</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Lipid Therapy</title>
            <description>aggressive lipid therapy: Crestor</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Events (MACE)</title>
          <description>MACE defined as a combined clinical endpoint of death, MI (Q wave or non Q-wave with CK-MB &gt;3 times above the upper normal limit (48 U/L), urgent revascularization or stroke at 30 days and 1 year. Details reported in adverse events section.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Chemistry - HsCRP</title>
        <description>Correlation of yellow plaque index with changes in levels of blood HsCRP as compared from baseline to 6-8 weeks after intervention</description>
        <time_frame>at baseline and at 6-8 weeks after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care Lipid Therapy</title>
            <description>standard-care lipid-lowering therapy: Zocor or Lipitor</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Lipid Therapy</title>
            <description>aggressive lipid therapy: Crestor</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Chemistry - HsCRP</title>
          <description>Correlation of yellow plaque index with changes in levels of blood HsCRP as compared from baseline to 6-8 weeks after intervention</description>
          <units>mg/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.7" upper_limit="3.4"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.8" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.7" upper_limit="4.7"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.7" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care Lipid Therapy</title>
          <description>standard-care lipid-lowering therapy: Zocor or Lipitor</description>
        </group>
        <group group_id="E2">
          <title>Aggressive Lipid Therapy</title>
          <description>aggressive lipid therapy: Crestor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Hospitalization for Chest Pain</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Any bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Statin discontinuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Statin dose reduction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST &gt; 3x ULN</sub_title>
                <description>aspartate aminotransferase (AST); upper limit of normal (ULN)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>ALT &gt; 3x ULN</sub_title>
                <description>alanine aminotransferase (ALT); upper limit of normal (ULN)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Periprocedural complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatine kinase-MB &gt; 5x ULN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Creatine kinase-MB &gt;10x ULN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Unplanned revascularization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations - small sample size and short duration of follow-up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Pedro R. Moreno</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <email>pedro.moreno@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

